Last reviewed · How we verify
nigella sativ
nigella sativ is a Small molecule drug developed by Tanta University. It is currently FDA-approved.
Nigella sativa is being studied as a potential treatment for children with beta thalassemia major. The exact mechanism of action of nigella sativa is not specified in the provided information, but it is being investigated as a therapeutic intervention in this condition.
At a glance
| Generic name | nigella sativ |
|---|---|
| Sponsor | Tanta University |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- nigella sativ CI brief — competitive landscape report
- nigella sativ updates RSS · CI watch RSS
- Tanta University portfolio CI
Frequently asked questions about nigella sativ
What is nigella sativ?
Who makes nigella sativ?
What development phase is nigella sativ in?
Related
- Manufacturer: Tanta University — full pipeline
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing